Few Turkish companies are experiencing such a transformational moment as GEN. Just in 2021, the Ankara-based organization made its public debut at the Istanbul Stock Exchange and signed an exclusive collaboration agreement with a Dutch biotech company for the development and commercialization of a therapy against Alzheimer’s and other neurodegenerative diseases.
GEN’s CEO, Abidin Gülmüş, comments on the recent developments, their international activities to become a major global pharma company and illustrates their unique business model: being the partner of choice for rare disease therapies in Turkey, generics manufacturing, and bold R&D investment.
The most important milestone achieved by GEN happened this year, when the company became public, listing its stock on the Istanbul Stock Exchange. Although it is only our 8th week of trading, we are happy with the results and the interest from investors.
